EMERGENT BIOSOLUTIONS INC (EBS) Stock Fundamental Analysis

NYSE:EBS • US29089Q1058

10.78 USD
+0.08 (+0.75%)
At close: Feb 18, 2026
10.51 USD
-0.27 (-2.5%)
Pre-Market: 2/19/2026, 8:31:45 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to EBS. EBS was compared to 521 industry peers in the Biotechnology industry. EBS has an average financial health and profitability rating. EBS has a valuation in line with the averages, but on the other hand it scores bad on growth.


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

  • EBS had positive earnings in the past year.
  • EBS had a positive operating cash flow in the past year.
  • The reported net income has been mixed in the past 5 years: EBS reported negative net income in multiple years.
  • The reported operating cash flow has been mixed in the past 5 years: EBS reported negative operating cash flow in multiple years.
EBS Yearly Net Income VS EBIT VS OCF VS FCFEBS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M -600M

1.2 Ratios

  • The Return On Assets of EBS (5.20%) is better than 91.36% of its industry peers.
  • EBS's Return On Equity of 13.03% is amongst the best of the industry. EBS outperforms 93.67% of its industry peers.
  • EBS's Return On Invested Capital of 6.57% is amongst the best of the industry. EBS outperforms 92.51% of its industry peers.
Industry RankSector Rank
ROA 5.2%
ROE 13.03%
ROIC 6.57%
ROA(3y)-20.7%
ROA(5y)-8.82%
ROE(3y)-57.28%
ROE(5y)-27.44%
ROIC(3y)N/A
ROIC(5y)N/A
EBS Yearly ROA, ROE, ROICEBS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 -40 -60 -80 -100

1.3 Margins

  • With an excellent Profit Margin value of 9.62%, EBS belongs to the best of the industry, outperforming 90.79% of the companies in the same industry.
  • Looking at the Operating Margin, with a value of 13.96%, EBS belongs to the top of the industry, outperforming 92.90% of the companies in the same industry.
  • Looking at the Gross Margin, with a value of 54.58%, EBS is in the better half of the industry, outperforming 76.78% of the companies in the same industry.
  • EBS's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 13.96%
PM (TTM) 9.62%
GM 54.58%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-15.64%
GM growth 5Y-10.6%
EBS Yearly Profit, Operating, Gross MarginsEBS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so EBS is destroying value.
  • The number of shares outstanding for EBS has been increased compared to 1 year ago.
  • Compared to 5 years ago, EBS has more shares outstanding
  • The debt/assets ratio for EBS is higher compared to a year ago.
EBS Yearly Shares OutstandingEBS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
EBS Yearly Total Debt VS Total AssetsEBS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.2 Solvency

  • Based on the Altman-Z score of 1.61, we must say that EBS is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of 1.61, EBS is in the better half of the industry, outperforming 65.45% of the companies in the same industry.
  • EBS has a debt to FCF ratio of 473.64. This is a negative value and a sign of low solvency as EBS would need 473.64 years to pay back of all of its debts.
  • EBS has a better Debt to FCF ratio (473.64) than 89.25% of its industry peers.
  • A Debt/Equity ratio of 1.14 is on the high side and indicates that EBS has dependencies on debt financing.
  • The Debt to Equity ratio of EBS (1.14) is worse than 75.62% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.14
Debt/FCF 473.64
Altman-Z 1.61
ROIC/WACC0.69
WACC9.46%
EBS Yearly LT Debt VS Equity VS FCFEBS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B

2.3 Liquidity

  • EBS has a Current Ratio of 5.76. This indicates that EBS is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 5.76, EBS is in the better half of the industry, outperforming 60.27% of the companies in the same industry.
  • EBS has a Quick Ratio of 3.15. This indicates that EBS is financially healthy and has no problem in meeting its short term obligations.
  • EBS has a worse Quick ratio (3.15) than 60.08% of its industry peers.
Industry RankSector Rank
Current Ratio 5.76
Quick Ratio 3.15
EBS Yearly Current Assets VS Current LiabilitesEBS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 275.22% over the past year.
  • Looking at the last year, EBS shows a very negative growth in Revenue. The Revenue has decreased by -29.91% in the last year.
  • Measured over the past years, EBS shows a decrease in Revenue. The Revenue has been decreasing by -1.15% on average per year.
EPS 1Y (TTM)275.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-22.63%
Revenue 1Y (TTM)-29.91%
Revenue growth 3Y-16.2%
Revenue growth 5Y-1.15%
Sales Q2Q%-21.34%

3.2 Future

  • The Earnings Per Share is expected to grow by 16.93% on average over the next years. This is quite good.
  • Based on estimates for the next years, EBS will show a small growth in Revenue. The Revenue will grow by 7.53% on average per year.
EPS Next Y767.9%
EPS Next 2Y-21.08%
EPS Next 3Y-46.24%
EPS Next 5Y16.93%
Revenue Next Year-26.68%
Revenue Next 2Y-8.09%
Revenue Next 3Y-15.25%
Revenue Next 5Y7.53%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
EBS Yearly Revenue VS EstimatesEBS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
EBS Yearly EPS VS EstimatesEBS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 2 -2 4 -4 6

More info and screens

Find the best growth stocksShow best growing peers

6

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 5.44, the valuation of EBS can be described as very cheap.
  • Based on the Price/Earnings ratio, EBS is valued cheaply inside the industry as 99.42% of the companies are valued more expensively.
  • Compared to an average S&P500 Price/Earnings ratio of 27.27, EBS is valued rather cheaply.
  • EBS is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE 5.44
Fwd PE N/A
EBS Price Earnings VS Forward Price EarningsEBS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of EBS indicates a rather cheap valuation: EBS is cheaper than 99.04% of the companies listed in the same industry.
  • 90.02% of the companies in the same industry are more expensive than EBS, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 404.4
EV/EBITDA 4.72
EBS Per share dataEBS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

  • EBS's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • EBS has a very decent profitability rating, which may justify a higher PE ratio.
  • A cheap valuation may be justified as EBS's earnings are expected to decrease with -46.24% in the coming years.
PEG (NY)0.01
PEG (5Y)N/A
EPS Next 2Y-21.08%
EPS Next 3Y-46.24%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for EBS!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

EMERGENT BIOSOLUTIONS INC

NYSE:EBS (2/18/2026, 7:26:26 PM)

Premarket: 10.51 -0.27 (-2.5%)

10.78

+0.08 (+0.75%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-29
Earnings (Next)02-26
Inst Owners76.29%
Inst Owner Change3.92%
Ins Owners2.43%
Ins Owner Change-3.04%
Market Cap566.17M
Revenue(TTM)788.90M
Net Income(TTM)75.90M
Analysts80
Price Target13.77 (27.74%)
Short Float %16.92%
Short Ratio10.23
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)553.46%
Min EPS beat(2)132.33%
Max EPS beat(2)974.59%
EPS beat(4)4
Avg EPS beat(4)319.17%
Min EPS beat(4)59.77%
Max EPS beat(4)974.59%
EPS beat(8)6
Avg EPS beat(8)233.65%
EPS beat(12)6
Avg EPS beat(12)57.5%
EPS beat(16)8
Avg EPS beat(16)-95.56%
Revenue beat(2)1
Avg Revenue beat(2)6.63%
Min Revenue beat(2)-4.69%
Max Revenue beat(2)17.94%
Revenue beat(4)2
Avg Revenue beat(4)-2.65%
Min Revenue beat(4)-24.3%
Max Revenue beat(4)17.94%
Revenue beat(8)4
Avg Revenue beat(8)6.03%
Revenue beat(12)8
Avg Revenue beat(12)11.69%
Revenue beat(16)10
Avg Revenue beat(16)8.03%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.19%
Valuation
Industry RankSector Rank
PE 5.44
Fwd PE N/A
P/S 0.72
P/FCF 404.4
P/OCF 43.55
P/B 0.97
P/tB 4.36
EV/EBITDA 4.72
EPS(TTM)1.98
EY18.37%
EPS(NY)-0.45
Fwd EYN/A
FCF(TTM)0.03
FCFY0.25%
OCF(TTM)0.25
OCFY2.3%
SpS15.02
BVpS11.09
TBVpS2.47
PEG (NY)0.01
PEG (5Y)N/A
Graham Number22.23
Profitability
Industry RankSector Rank
ROA 5.2%
ROE 13.03%
ROCE 8.31%
ROIC 6.57%
ROICexc 8.06%
ROICexgc 13.89%
OM 13.96%
PM (TTM) 9.62%
GM 54.58%
FCFM 0.18%
ROA(3y)-20.7%
ROA(5y)-8.82%
ROE(3y)-57.28%
ROE(5y)-27.44%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-15.64%
GM growth 5Y-10.6%
F-Score6
Asset Turnover0.54
Health
Industry RankSector Rank
Debt/Equity 1.14
Debt/FCF 473.64
Debt/EBITDA 3.18
Cap/Depr 11.8%
Cap/Sales 1.47%
Interest Coverage 2.21
Cash Conversion 6.24%
Profit Quality 1.84%
Current Ratio 5.76
Quick Ratio 3.15
Altman-Z 1.61
F-Score6
WACC9.46%
ROIC/WACC0.69
Cap/Depr(3y)106.07%
Cap/Depr(5y)126.37%
Cap/Sales(3y)13.29%
Cap/Sales(5y)12.46%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)275.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-22.63%
EPS Next Y767.9%
EPS Next 2Y-21.08%
EPS Next 3Y-46.24%
EPS Next 5Y16.93%
Revenue 1Y (TTM)-29.91%
Revenue growth 3Y-16.2%
Revenue growth 5Y-1.15%
Sales Q2Q%-21.34%
Revenue Next Year-26.68%
Revenue Next 2Y-8.09%
Revenue Next 3Y-15.25%
Revenue Next 5Y7.53%
EBIT growth 1Y195.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year367.47%
EBIT Next 3Y55.51%
EBIT Next 5Y39.09%
FCF growth 1Y100.65%
FCF growth 3Y-28.05%
FCF growth 5Y-17.04%
OCF growth 1Y108.93%
OCF growth 3Y-43.25%
OCF growth 5Y-20.77%

EMERGENT BIOSOLUTIONS INC / EBS FAQ

Can you provide the ChartMill fundamental rating for EMERGENT BIOSOLUTIONS INC?

ChartMill assigns a fundamental rating of 4 / 10 to EBS.


Can you provide the valuation status for EMERGENT BIOSOLUTIONS INC?

ChartMill assigns a valuation rating of 6 / 10 to EMERGENT BIOSOLUTIONS INC (EBS). This can be considered as Fairly Valued.


What is the profitability of EBS stock?

EMERGENT BIOSOLUTIONS INC (EBS) has a profitability rating of 6 / 10.


Can you provide the PE and PB ratios for EBS stock?

The Price/Earnings (PE) ratio for EMERGENT BIOSOLUTIONS INC (EBS) is 5.44 and the Price/Book (PB) ratio is 0.97.


How financially healthy is EMERGENT BIOSOLUTIONS INC?

The financial health rating of EMERGENT BIOSOLUTIONS INC (EBS) is 4 / 10.